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Several lines of evidence suggest that genetic factors might contribute to drug abuse 
vulnerability. Recent genomic scans for association demonstrated that the brain-derived 
neurotrophic factor (BDNF) gene was associated with drug abuse vulnerability. In this study, we 
analyzed association of two BDNF gene single nucleotide polymorphisms (SNPs), 132C>T 
(C270T named formerly) in the noncoding region of exon V and 196G >A (val66met) in the 
coding region of exon XIIIA, with methamphetamine (MAP) abuse in Japan. No significant 
differences were found in the frequency of the genotype or allele in these two SNPs between 
MAP abusers and controls (132C>T in exon V: genotype, p = 0.586, allele, p = 0.594; 196G>A 
(val66met) in exon XIIIA: genotype, p = 0.889, allele, p = 0.713). Furthermore, there was no 
difference between clinical parameters (e.g. prognosis psychosis, spontaneous relapse, or 
poly-substance abuse) and the two SNPs of BDNF gene. These results suggest that the two 
SNPs (132C>T in exon V and 196G>A (val66met) in exon XIIIA) of the BDNF gene may not 
be associated with Japanese MAP abusers.  
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Introduction 
Family, twin and adoption studies suggest that genetic factors are implicated in 
vulnerability of substance abuse (Merikangas et al, 1998; Kendler, 2001; Kendler et al, 2000; 
Tsuang et al, 2001). The genome-scanning study of poly-substance abuse vulnerability 
demonstrated that the brain-derived neurotrophic factor (BDNF) gene might be one of the 
strong candidate genes to drug abuse (Uhl et al., 2001). BDNF is a member of a neurotrophin 
superfamily mainly expressed within the brain. BDNF interacts with TrkB receptor tyrosine 
kinase, playing several important roles such as; promotion of survival, differentiation and 
maintenance of neurons in peripheral nervous system and central nervous system; influences to 
axonal growth and connectivity; participation in the local responses to various types of neuronal 
stress or insults (Manji et al, 2003; Mattson et al, 2003). Furthermore, it also has been reported 
that the gene encoding BDNF might be an important candidate for susceptibility of 
neuropsychiatric disorders including bipolar disorder (Neves-Pereira et al, 2002; Sklar et al, 
2002; Hashimoto et al, 2004), schizophrenia (Krebs et al, 2000), Parkinson’s disease (Momose 
et al, 2002), and Alzheimer’s disease (Ventriglia et al, 2002). In the studies reporting possible 
association of BDNF and these disorders, two SNPs of BDNF gene has been reported. One is 
196G>A (val66met) SNP in exon XIIIA (GENBANK: AF411339; at position 95422) located 
within the propeptide region of BDNF. The A of the ATG-translation initiation codon is denoted 
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nucleotide +1 in exon XIIIA (GENBANK: AF411339; at position 95227). Sklar et al (2002) 
reported that BDNF 196G>A (val66met) is significantly associated with bipolar disorder. 
Interestingly, it has been demonstrated that this SNP (val66met) is strongly suspected to 
influence human memory and hippocampal function (Egan et al, 2003). Several lines of 
evidence demonstrated that MAP dependence may cause long-term neural damage in humans, 
with concomitant deleterious effects on cognitive processes such as memory and attention 
(Nordahl et al, 2003), suggesting the possible role of BDNF secretion in the memory deficits of 
MAP abusers. The other SNP frequently analyzed is 132C>T in the noncoding region of exon V 
(GENBANK: AF411339; at position 53620). This SNP at position 132 of exon V is numbered 
from the start of exon V (GENBANK: AF411339; at position 53488). It was detected and 
named C270T by Kunugi et al. (2001) after their searching for a novel nucleotide substitution in 
the noncoding region of the BDNF gene reported by Shintani et al (1992). It has been reported 
that the 132C>T in exon V of the BDNF gene was significantly associated with late-onset 
Alzheimer’s disease (Kunugi et al, 2001), Alzheimer’s disease lacking the Apolipoprotein E ε4 
allele (Riemenschneider et al, 2002), or schizophrenia (Szekeres et al, 2003). In addition, it has 
been reported that the BDNF 196G>A (val66met) is associated with personality traits in healthy 
subjects (Itoh et al, 2004; Sen et al, 2003), suggesting the role of BDNF gene in personality 
traits and temperament. Considering the role of personality traits in substance use disorders 
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(Howard et al, 1997), it is likely that the BDNF gene may be implicated in the vulnerability of 
drug abuse.  
Methamphetamine (MAP) is the most popular abused drug in Japan. Use of MAP induces a 
strong psychological dependence, and repeated usage frequently results in psychotic states, 
which symptoms are similar to those of paranoid-type schizophrenia (Sato et al, 1992; Ujike, 
2002). It has been demonstrated that BDNF plays a role in the survival and differentiation of 
midbrain dopaminergic neurons in vivo (Hyman et al., 1991) and in vitro (Spina et al., 1992), 
and that chronic BDNF treatment enhances locomotor activity and conditioned reward to 
cocaine (Horger et al., 1999). In addition, it is likely that BDNF could modulate the release of 
dopamine through the activation of TrkB receptors (Blochl and Sirrenberg, 1996). Furthermore, 
it has been reported that locomotor behaviors by amphetamine was increased to a greater degree 
in the BDNF heterozygous (+/-) knock-out mice, and that striatal dopamine concentrations were 
significantly higher in the BDNF heterozygous (+/-) knock-out mice (Dluzen et al, 2001). 
Moreover it has been reported recently that pretreatment with intra-nucleus accumbens injection 
of BDNF antibody or TrkB antibody suppressed significantly the release of dopamine and 
dopamine-related behaviors induced by administration of MAP, suggesting the implication of 
BDNF in MAP-induced dopamine release and MAP-induced abnormal behaviors (Narita et al, 
2003). Taken together, it is of interest to study the influences of the BDNF gene SNPs in MAP 
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abuse vulnerability. In this study, we analyzed the frequency of two known SNPs (196G>A 
(val66met) in exon XIIIA and 132C>T in exon V) of BDNF gene between MAP abusers and 
healthy subjects in Japan.  
 
MATERIALS AND METHODS 
Subjects and samples 
This study was performed after obtaining the approval of the ethics committees of each 
affiliated institute of the Japanese Genetics Initiative for Drug Abuse (JGIDA). All subjects 
provided written informed consent for the use of their DNA samples for this study. The subjects 
were 189 patients (150 males and 39 female; age, 36.6 ± 11.9 (mean ± S.D.)) with MAP 
dependence and a psychotic disorder meeting the ICD-10-DCR criteria (F15.2 and F15.5) who 
were outpatients or inpatients of psychiatric hospitals of the JGIDA. Two hundred and two 
volunteers were recruited as healthy controls. All controls have no significant lifetime history of 
use of any addictive substance (158 males and 44 females; 37.2 ± 10.6 (mean ± S.D.)), the 
majority of whom were medical staff with no past history and no family history of drug 
dependence or psychotic disorders. Diagnoses were made by two trained psychiatrists by 
interview and available information including hospital records. Patients were excluded if they 
had a clinical diagnosis of schizophrenia, another psychotic disorder, or an organic mental 
syndrome as reported previously. All subjects were Japanese, born and living in restricted areas 
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of Japan including northern Kyushu, Setouchi, Tyukyou, Toukai, and Kantou.  
The patients were divided into subgroups by some characteristic clinical features. The 
patients were divided by poly-substance abuse status, 56 patients abuse MAP only in their 
lifetime, and 122 patients abuse some other drugs besides MAP in present or past. Organic 
solvent was most frequently abused besides MAP, followed by marijuana. Cocaine and heroine 
were rarely abused in the present study. Prognosis of MAP psychosis was various among 
patients, and some patients showed continuous psychotic symptoms even after MAP 
discontinuance as previously reported (Sato et al, 1992; Ujike, 2002). Therefore, patients were 
divided into two categories of prognosis, transient-type and prolonged-type, based on duration 
of psychotic state after MAP discontinuance. Thus, patients with transient-type whose psychotic 
symptoms improves within one month after discontinuance of MAP consumption and beginning 
of treatment with antipsychotic drugs, and those with prolonged-type whose psychosis 
continues for more than one month even after discontinuance of MAP consumption and 
beginning of treatment. In this study, patients with transient- and prolonged-types of MAP 
psychosis were 94 and 66, respectively. It has been well documented that once MAP psychosis 
has developed, patients in remission state becomes reliable to spontaneous relapse without 
re-consumption of MAP (Sato et al, 1992; Ujike, 2002). It is postulated that sensitization 
phenomenon induced by repeated consumption of MAP should be developed in the brain of 
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MAP psychosis patients which result in neural basis for enhanced susceptibility to relapse. 
Therefore, the patients were divided into two groups according to presence or absence of 




The genomic DNA was extracted from peripheral leukocytes by standard procedures. 
Polymerase chain reaction (PCR) and the PCR-based restriction fragment length polymorphism 
(RFLP) assay were performed to genotype the DNA sequence variants of the BDNF gene. PCR 
was carried out in a total volume of 25 μl with 1 units of Ex Taq DNA polymerase (Takara 
Shuzo Ltd., Kyoto, Japan) in the reaction mixture. The primer sequences for analysis of 
val66met (196G>A) (GENBANK: AF411339; at position 95422) in exon XIIIA (position 
95206-98892) were forward: 5’-GGTGAGAAGAGTGATGACCA-3’ (position 95214-95233) 
and reverse: 5’-GCCAGCCAATTCTCTTTTTG-3’ (position 95892-95911). The former 
contains the first met and the second thr (MT), while the latter contains 223lys, 224lys, 225arg, 
226ile, 227gly and 228trp (KKRIGW). The primer sequences for analysis of 132C>T 
(GENBANK: AF411339; at position 53620) in exon V (position 53488-53644) were the 
forward primer 5’-CAGAGGAGCCAGCCCGGTGCG-3’ (position 53458-53478) and the 
reverse primer 5’-CTCCTGCACCAAGCCCCATTC-3’ (position 53660-53680).  
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The amplification conditions were initiated at 94˚C for 4 min, followed by 32 cycles 
consisting of denaturation at 94˚C for 30 s, annealing at 58˚C for 30 s and extention at 72˚C for 
30 s, with a final extention step of 7 min at 72˚C. The PCR products were digested at 37˚C with 
restriction enzyme PmaC I (Takara Shuzo Ltd., Kyoto, Japan) for analysis of 196G>A 
(val66met) in exon XIIIA or HinfI (Takara Shuzo Ltd., Kyoto, Japan) for analysis of 132C>T in 
exon V, followed by 2 % or 4 % agarose gel- electrophoresis with ethidium bromide staining, 
respectively.  
Statistical analysis 
Fisher’s exact test was used for categorical comparisons, and Student’s t-test was employed 
for age difference. Significance for the results was set at p < 0.05. 
 
RESULTS 
Both the genotype and allele frequencies for the patients and controls are shown in Table 1 
and Table 2. The genotype distribution for patients groups and control groups did not deviate 
significantly from the Hardy-Weinberg equilibrium. No significant differences were found in the 
frequency of the genotype or allele in these two SNPs between patients and controls (132C>T in 
exon V: genotype, p = 0.586, allele, p = 0.594; 196G>A (val66met) in exon XIIIA: genotype, p 
= 0.889, allele, p = 0.713). As for the 132C>T substitution, there was no individual who was 
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homozygous for the 132T allele in exon V. Within patients, we analyzed the effects of prognosis 
psychosis (transient or prolonged), spontaneous relapse (positive or negative), and 
poly-substance abuse (yes or no) on the BDNF gene SNPs (132C>T in exon V and 196G>A in 
exon XIIIA). The genotypic and allelic distribution of two SNPs was not significantly different 
between transient type of psychosis and prolonged type of psychosis (Table 1 and 2). 
Furthermore, the genotypic and allelic distribution of two SNPs was not significantly different 
between positive spontaneous relapse and negative spontaneous relapse (Table 1 and 2). 
Moreover, the genotypic and allelic distribution of two SNPs was not significantly different 
between poly-substance abuse and non-poly-substance abuse (Table 1 and 2). In addition, we 
found that two SNPs were not in linkage disequilibrium with each other.   
 
DISCUSSION 
The present study suggests that two SNPs (132C>T in exon V and 196G>A (val66met) in 
exon XIIIA) of the BDNF gene may not be susceptible to MAP-abuse in Japanese samples. 
Using a European American sample and an African American sample, it has been reported that 
the BDNF gene could contribute to vulnerabilities to poly-substance abuse (Uhl et al, 2001). It 
is possible that difference in ethnicity might contribute to discrepancy between our study and 
other study. Frequency of A allele of 196G>A (val66met) in Japanese population (Momose et al, 
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2002; Nakata et al, 2003; Itoh et al, 2004; this study) is higher than that of Caucasian population 
(Ventriglia et al, 2002; Egan et al, 2003; Hakansson et al, 2003; Sen et al, 2003), suggesting the 
ethnic difference in this SNP (val66met)(Shimizu et al, 2004). First, it has been reported that the 
196G>A (val66met) of the BDNF gene is associated with Parkinson’s disease in Japanese 
subjects (Momose et al, 2002). However, lack of association between the BDNF 196G>A 
(val66met) and Parkinson’s disease in a Swedish population was reported (Hakansson et al, 
2003). Second, it has been reported that the 196G>A (val66met) of the BDNF gene is associated 
with bipolar disorder in Caucasian (Neves-Pereira et al, 2002; Sklar et al, 2002). However, no 
association between 196G>A (val66met) of the BDNF gene and bipolar disorder in Japanese 
population was detected (Nakata et al, 2003), suggesting that the BDNF gene may confer a 
susceptibility to bipolar disorder in Caucasian, but not in Japanese population. Thus, it is likely 
that ethnic differences may contribute to inconsistent findings between Caucasian sample and 
Japanese sample.  
In this study, we investigated two SNPs; one (132C>T in exon V) in the noncoding region 
and the other (196G>A (val66met) in exon XIIIA) in the coding region. Whereas BDNF 
196G>A (val66met) SNP does not affect the function of a mature BDNF protein, it has been 
shown to dramatically alter the intracellular trafficking and packaging of pro-BDNF, and, thus, 
the regulated secretion of the mature BDNF protein (Egan et al, 2003). At cellular levels, 
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marked deficits were observed in the intracellular distribution, processing, and secretion of 
met-BDNF, suggesting that pro-BDNF may play a critical role in synaptic targeting and 
activity-dependent secretion at synapses (Egan et al, 2003). Remarkably, healthy human 
subjects with the met allele exhibit impaired hippocampal activity and memory function (Egan 
et al, 2003). However, it is currently unknown whether the BDNF 132C>T SNP could affect on 
the function, synthesis or secretion of BDNF. There are still other known SNPs in the BDNF 
gene sequences, and it is possible that there are more unknown SNPs. Further studies of other 
SNPs and unknown SNPs should be done to clarify the involvement of the BDNF gene in 
substance abuse vulnerability. 
In conclusion, we failed to detect evidence for a role of two SNPs (196G>A (val66met) in 
exon XIIIA and 132C>T in exon V) of the BDNF gene in the pathogenesis of MAP abusers in 
our Japanese sample. Therefore, it is unlikely that the two SNPs (196G>A (val66met) in exon 
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Table 1. Genotype and allele frequencies of the BDNF 132C>T (in exon V) gene polymorphism of in controls and MAP abusers 
 
132C>T  n Genotype     p  Allele    p 
   CC  CT  TT    C  T 
 
Control  202 183 (90.6 %) 19 (9.4 %) 0 (0 %)    385 (95.3 %) 19 (4.7 %)  
  
Abuser  189 175 (92.6 %) 14 (7.4 %) 0 (0 %)  0.586  364 (96.3 %) 14 (3.7 %) 0.594 
 
Prognosis of Psychosis 
Transient    94    87 (92.6 %)     7 (7.4 %)        0 (0 %)  0.664           181 (96.3 %)     7 (3.7 %) 0.671 
Prolonged   66    62 (93.9 %)     4 (6.1 %)        0 (0 %)  0.612           128 (97.0 %)     4 (3.0 %) 0.620 
 
Spontaneous Relapse 
Positive     64    60 (93.8 %)     4 (6.3 %)        0 (0 %)  0.611           124 (96.9 %)     4 (3.1 %) 0.619 
Negative   116   107 (92.2 %)     9 (7.8 %)        0 (0 %)  0.685           223 (96.1 %)     9 (3.9 %) 0.692 
 
Poly-substance Abuse 
No        56     51 (91.1 %)     5 (8.9 %)        0 (0 %)  1              107 (95.5 %)     5 (4.5 %)  1 
Yes      122    114 (93.4 %)     8 (6.6 %)        0 (0 %)          0.414          236 (96.7 %)     8 (3.3 %)  0.424 
 





Table 2. Genotype and allele frequencies of the BDNF 196G>A (val66met)(in exon XIIIA) gene polymorphism in controls and MAP abusers 
 
196G>A  n Genotype     p  Allele    p 
(val66met)  GG  GA  AA    G  A 
 
Control  202 70 (34.7 %) 107 (53.0 %) 25 (12.4 %)   247 (61.1 %) 157 (38.9 %) 
 
Abuser   189 70 (37.0 %) 96 (50.8 %) 23 (12.2 %) 0.889  236 (62.4 %) 142 (37.6 %) 0.713 
 
Prognosis of Psychosis 
Transient    94    32 (34.0 %)     53 (56.4 %)       9 (9.6 %) 0.778          117 (62.2 %)     71 (37.8 %) 0.856 
Prolonged   66    25 (37.9 %)     30 (45.5 %)      11 (16.7 %) 0.472           80 (60.6 %)      52 (39.4 %) 0.918 
 
Spontaneous Relapse 
Positive     64    27 (42.2 %)     30 (46.9 %)       7 (10.9 %) 0.571             84 (65.6 %)     44 (34.4 %) 0.403 
Negative   116    39 (33.6 %)     62 (53.4 %)      15 (12.9 %) 0.972            140 (60.3 %)     92 (39.7 %) 0.866 
 
Poly-substance Abuse 
No        56     21 (37.5 %)     27 (48.2 %)       8 (14.3 %) 0.791            69 (61.6 %)     43 (38.4 %) 1 
Yes      122     47 (38.5 %)     60 (49.2 %)       15 (12.3 %) 0.762           154 (63.1 %)     90 (36.9 %) 0.676 
 
Statistical analysis was performed by a Fisher’s exact test (vs. Control). 
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